Apellis Pharmaceuticals, Inc.NASDAQ: APLS

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

· Issued by Apellis Pharmaceuticals, Inc.
Watch Apellis Pharmaceuticals explain itApellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call · Replay · Feb 24
  • Pegcetacoplan met the primary endpoint in the PEGASUS study, demonstrating superiority to eculizumab (p

Company analysis